STAT+: Biotech leaders say uncertainty at FDA threatens drug development
BOSTON — Replimune Group and Capricor Therapeutics both seemed on track to receive long-awaited drug approvals from the Food and Drug Administration earlier this year. Then, amid tumult at the agency as
